Abstract: International patent application WO99/61053 discloses immunogenic compositions that comprise N. meningitidis serogroup C oligosaccharide conjugated to a carrier, in combination with N. meningitidis serogroup B outer membrane protein. These are disclosed in the present application in combination with further Neisserial proteins and/or protective antigens against other pathogenic organisms (e.g. Haemophilus influenzae, DTP, HBV, etc.).

Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.

Abstract: The present disclosure provides an immersion vaccine for fish comprising at least one isolated antigen, specifically a recombinant antigen, such as is F. psychrophilum and/or infectious pancreatic necrosis virus (IPNV).

Abstract: The present invention provides an immunogenic composition of a lipopolysaccharide vaccine and a non-alum adjuvant. The immunogenic composition may be detoxified J5 core lipopolysaccharide of Escherichia coli non-covalently complexed with group B meningococcal outermembrane protein. Also provided are methods for preventing an infection caused by a Gram-negative bacteria in an individual via administering the immunogenic compositions to the individual.

Abstract: The present invention relates to an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Methods of making and uses thereof are also described.

Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.

Abstract: The present invention relates to an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. The present invention also relates to a composition comprising an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same.

Abstract: The present invention relates to immunological compositions and vaccines that target diseases caused by infection with Streptococcus pyogenes. In particular, the compositions of the present invention find use in therapeutic and/or prophylactic methods for the treatment or prevention of morbidity associated with infection with Streptococcus pyogenes. The present invention also relates to methods of making the immunological compositions and vaccines as well as methods for producing stable SpeAB antigen formulations in combination with one or more additional immunologically active substituents (e.g., adjuvants).

Abstract: The present invention concerns VLPT immunoreactive compositions for E. chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. chaffeensis VLPT are disclosed.

Abstract: Disclosed herein are microbiocidal compositions that include spore-forming strains of Bacillus. The compositions may be utilized to treat or prevent disease in aquatic animals such as farmed fish or crustaceans.

Abstract: The present invention concerns VLPT immunoreactive compositions for E. chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. chaffeensis VLPT are disclosed.

Abstract: The present invention concerns gp19 immunoreactive compositions for E. canis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. canis gp19 are disclosed.

Abstract: The present invention concerns gp19 immunoreactive compositions for E. canis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. canis gp19 are disclosed.

Abstract: The invention provides novel immunological adjuvants and methods for identification of such adjuvants. The invention further provides methods and compositions for eliciting an immune response to an immunogen using the novel adjuvants. The adjuvants can be employed with any suitable immunogen, including proteins, peptides, lipids, and carbohydrates. The immunogen can be derived from a virus, a cancer, or a diseased cell. The elicited immune response can be cellular, humoral, or both.

Abstract: The present invention relates to a novel hybrid/fusion protein derived from the CS protein of Plasmodium vivax (P. vivax), methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, for example those caused by P. vivax, compositions/vaccines containing the protein or antibodies against the protein such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. The invention also extends to lipoprotein particles of said hybrid protein and formulations/vaccines comprising the same and use thereof. In particular it relates to an immunogenic hybrid fusion protein comprising: a. at least one repeat unit derived from the repeating region of a type I circumsporozoite protein of P. vivax, b. at least one repeat unit derived from the repeating region of a type II circumsporozoite protein of P. vivax, and surface antigen S derived from Hepatitis B virus, or a fragment thereof.

Abstract: This disclosure provides attenuated Histophilus somni strains, compositions comprising same, and methods of production and use thereof. The attenuated strains may express lower or no levels of various virulence-associated genes, relative to the corresponding pathogenic bacteria Advantageously, the attenuated Histophilus somni strains may be administered orally, intranasally, intra-tracheally, or subcutaneously.

Abstract: fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a host animal.

Abstract: Disclosed are methods and compositions for treating or preventing a Staphylococcus bacterial infection using a non-toxigenic Protein A (SpA) variant.

Abstract: This invention relates to assays for a Plasmodium analyte in a liquid sample such as a body fluid. More particularly, the invention relates to a method and apparatus for the detection of a ligand in a body fluid such as urine or blood, which can diagnose malarial infection.

Abstract: This document provides methods and materials related to Prevotella histicola preparations. For example, Prevotella histicola preparations in the form of an oral medicament or dietary supplement (e.g., a pill, tablet, capsule) are provided. In addition, methods and materials for using a Prevotella histicola preparation provided herein as an anti-inflammatory agent are provided.